On the recordJuly 15, 2013
Under the proposed Senate framework, FDA would be barred from requiring compounding manufacturers to submit NDAs and ANDAs pre-inspection and labeling requirements before these drugs reach patients.
Source
congress.govJoe Pitts: “Under the proposed Senate framework, FDA would be barred from requiring compounding manufacturers to submit NDAs and…”
Editor's note · Context
Pitts highlights concerns about FDA's regulatory limitations on compounding manufacturers.
Share
More from Joe Pitts
Dec 6, 2016
The jurisdictional grab serves only to shield catfish farmers against competition at the expense of U.S. consumers.
Sep 13, 2016
It is unfortunate that we have a Congress of the United States, the majority parties that want to just tear down this law.
Dec 6, 2016
It seems illogical that the USDA would be given the exclusive authority to oversee and regulate catfish only while the FDA regulates all other seafood.
Other voices in this conversation
